Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492203 | 1.00 | PTPN1 (0.47) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL21552147 | 0.98 | PTPN1 (0.48) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL21552149 | 0.98 | PTPN1 (0.48) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL30054532 | 0.91 | MDM2 (0.49) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL23728661 | 0.91 | MDM2 (0.53) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL30523139 | 0.91 | MDM2 (0.53) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL23728660 | 0.91 | MDM2 (0.53) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL17697136 | 0.91 | MDM2 (0.53) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL7971614 | 0.89 | PTPN1 (0.47) | PTPN1MDM2MDM4TP53TLR2 | |
| SCHEMBL31720035 | 0.89 | PTPN1 (0.47) | PTPN1MDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265842-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3716982-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265842-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | CD40, CD40LG, FCGRT | PTPN1 218/4885MDM2 1711/4885MDM4 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.